Managing antithrombotic therapy in high-risk cardiovascular patients undergoing neurovascular revascularization presents difficult clinical choices. Clinicians routinely face complex therapeutic trade-offs when considering carotid artery stenting anticoagulation in patients with coexisting atrial fibrillation. Although dual antiplatelet therapy provides essential protection against acute stent thrombosis, adding full-dose oral anticoagulants markedly escalates major bleeding risks. Conversely, interrupting anticoagulation leaves patients vulnerable to disabling cardioembolic stroke. Consequently, clinicians need pragmatic, standardized protocols that maintain stent patency while controlling hemorrhagic complications during elective procedures.

The Dilemma of Carotid Artery Stenting Anticoagulation

Carotid artery stenting serves as an effective revascularization technique for significant carotid stenosis, especially in anatomically challenging surgical necks. However, standard post-stenting protocols mandate rigorous dual antiplatelet therapy with aspirin and a P2Y12 inhibitor to prevent acute thrombotic occlusion over metallic struts. In patients with concurrent non-valvular atrial fibrillation, continuing therapeutic oral anticoagulants alongside dual antiplatelet therapy generates an aggressive triple antithrombotic regimen. Cardiology trials previously demonstrated that triple antithrombotic therapy exponentially amplifies major bleeding complications without providing proportional ischemic advantages.

Furthermore, neurovascular interventions carry sensitive bleeding risks, such as expanding cervical neck hematomas and intracranial hemorrhagic transformations. Conversely, discontinuing anticoagulants or using heparin bridging introduces dangerous therapeutic gaps and prothrombotic rebounds. Therefore, evaluating carotid artery stenting anticoagulation strategies that combine uninterrupted oral anticoagulants with short-term single antiplatelet therapy addresses a vital clinical dilemma. By limiting platelet inhibition while maintaining uninterrupted anticoagulation, interventional teams aim to suppress acute stent thrombosis while significantly reducing systemic hemorrhage.

Real-World Cohort and Procedural Protocol

To evaluate this antithrombotic combination, investigators analyzed a prospectively maintained registry of consecutive adult patients undergoing elective carotid artery stenting between 2020 and 2025. The clinical protocol required patients to continue therapeutic oral anticoagulation without interruption throughout the peri-procedural period. Additionally, clinicians prescribed a single antiplatelet agent at least five days prior to carotid stenting. Patients then maintained this dual antithrombotic therapy for at least thirty days post-procedure.

The study cohort comprised thirty consecutive patients with a mean age of 77.4 years, representing an elderly and frail population. Men constituted 76.7 percent of the participants. Non-valvular atrial fibrillation represented the predominant indication for chronic anticoagulation, accounting for 73.3 percent of cases. Furthermore, direct oral anticoagulants were the primary anticoagulant class, administered to two-thirds of the cohort, while vitamin K antagonists accounted for the remainder. This observational study provides meaningful real-world insight into whether uninterrupted anticoagulation paired with single antiplatelet coverage can safely prevent ischemic complications while avoiding severe hemorrhagic events.

Efficacy, Safety Endpoints, and Patency Rates

The primary outcome assessed thirty-day net adverse clinical events, combining major ischemic and hemorrhagic complications. Net adverse events occurred in two patients, yielding a low thirty-day incidence of 6.7 percent. Specifically, one patient experienced an ischemic stroke caused by subacute in-stent thrombosis, whereas one patient experienced major gastrointestinal bleeding. Importantly, no procedural deaths, intracranial hemorrhages, or fatal bleeding episodes occurred during the monitoring period.

Moreover, post-procedure vascular imaging confirmed persistent stent patency at thirty days in all patients without early adverse events. This objective confirmation allowed the medical team to discontinue the single antiplatelet agent safely after one month, transitioning patients back to oral anticoagulation monotherapy. Functional status remained favorable, with 86.7 percent of participants achieving a modified Rankin Scale score of two or lower at one month, and 83.3 percent maintaining functional independence at three months. These encouraging outcomes demonstrate that uninterrupted anticoagulation combined with short-term single antiplatelet therapy provides acceptable short-term safety in selected elective patients.

Mechanisms of Hemostasis and Thrombosis Prevention

Achieving an optimal antithrombotic balance requires understanding how distinct pharmacological agents interact within the vasculature. Carotid stent deployment causes mechanical endothelial disruption, exposing subendothelial collagen and triggering immediate platelet adhesion and aggregation. Standard neurointerventional practice relies on intensive platelet suppression to overcome this initial thrombogenic response until a neointimal layer coats the metal mesh. However, sustained platelet inhibition combined with systemic anticoagulation substantially compromises primary hemostasis.

Because carotid arteries have larger diameters and higher blood flow velocities than coronary vessels, shear forces and rheological conditions differ markedly. Consequently, prolonged triple therapy confers excessive bleeding liability, particularly in elderly patients with cerebral microbleeds or renal insufficiency. By restricting antiplatelet therapy to a single agent and shortening exposure to thirty days, the evaluated regimen curbs platelet suppression effectively. Meanwhile, uninterrupted oral anticoagulation maintains systemic protection against cardioembolic events and atrial thrombi. This rational approach minimizes systemic bleeding vulnerabilities while sustaining sufficient local thrombotic protection during early vessel healing.

Translating Findings into Interventional Practice

Integrating these findings into routine clinical practice requires careful individualized risk stratification and meticulous interventional execution. Clinicians should evaluate patient-specific factors, including baseline renal function, prior bleeding history, hypertension control, and ischemic burden. When choosing the single antiplatelet agent, clopidogrel remains the most widely utilized partner, although clinicians should remain mindful of variable metabolic responsiveness. Additionally, operators should emphasize meticulous stent deployment to guarantee complete lesion coverage and optimal wall apposition.

Furthermore, utilizing distal embolic protection devices and ultrasound-guided vascular access substantially reduces procedural embolization and groin hematomas. Following successful stent placement, clinicians must schedule duplex ultrasound surveillance at thirty days to verify stent patency before de-escalating therapy. Once duplex imaging confirms patent flow, discontinuing the antiplatelet drug and continuing oral anticoagulation monotherapy minimizes long-term bleeding hazards. Although larger prospective multicenter trials are needed to validate these observational results, this standardized regimen offers a practical, balanced roadmap for managing anticoagulated patients who require elective carotid stenting.

Frequently Asked Questions

Why is triple therapy avoided in carotid artery stenting?

Triple antithrombotic therapy substantially multiplies major bleeding risks, including intracranial hemorrhage and puncture-site hematomas, without providing proven additional ischemic protection. Clinical experience across vascular specialties indicates that dual therapy, combining an anticoagulant with one antiplatelet agent, significantly improves overall safety while maintaining sufficient protection against acute arterial occlusion.

How long should single antiplatelet therapy continue alongside anticoagulation?

The standard protocol maintains single antiplatelet therapy for thirty days following carotid artery stenting. This thirty-day duration protects against acute and subacute in-stent thrombosis during initial vessel endothelialization. Once vascular ultrasound confirms stent patency at one month, clinicians can safely discontinue the antiplatelet agent and continue anticoagulant monotherapy.

What are the primary benefits of uninterrupted oral anticoagulation during stenting?

Maintaining uninterrupted oral anticoagulation preserves continuous protection against cardioembolic stroke in high-risk patients with atrial fibrillation. Additionally, this uninterrupted strategy avoids the rebound thromboembolic risks, administrative complexities, and heightened access-site bleeding complications that frequently accompany bridging therapy with low-molecular-weight heparin or unfractionated heparin.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Healthcare professionals should exercise their independent clinical judgment and verify all information prior to making clinical decisions. Refer to the latest local and national guidelines for clinical practice.

References

1. Barbella G et al. Uninterrupted oral anticoagulation plus short-term single antiplatelet therapy in anticoagulated patients undergoing carotid artery stenting. Clin Neurol Neurosurg. 2026 Sep. doi: 10.1016/j.clineuro.2026.109513. PMID: 42190493.
2. Kumbhani DJ, Cannon CP, Beavers CJ, et al. 2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or With Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2021;77(5):629-658.
3. Bonati LH, Kakkos S, Berkefeld J, et al. European Stroke Organisation guideline on endarterectomy and stenting for carotid artery stenosis. Eur Stroke J. 2021;6(2):I-XLVII.